CAR-T(CAR-T)细胞疗法在非肿瘤性疾病中的应用
Chimeric antigen receptor T (CAR-T) cell therapy in non-oncological diseases.
CAR-T(CAR-T)细胞在血液系统恶性肿瘤中的应用推动了这种免疫治疗形式的显著进展。
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
英文原题:Digital PCR Improves Sensitivity and Quantification in Monitoring CAR-T Cells in B Cell Lymphoma Patients.
Digital PCR Improves Sensitivity and Quantification in Monitoring CAR-T Cells in B Cell Lymphoma Patients.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
CAR-T 细胞已成为一种有前景的疗法,但超过60%的患者未能维持长期缓解。导致该疗法有效性的潜在因素尚未完全明确,CAR-T 细胞的持续存在和监测似乎对于确保成功应答至关重要。已应用多种监测方法,如多参数流式细胞术(MFC)或定量PCR(qPCR)。我们的目标是开发用于检测和定量CAR-T 细胞的数字PCR(dPCR)方法,并将其与MFC和qPCR进行比较。分析了45例接受CAR-T 治疗患者在不同随访时间采集的样本,以评估不同方法之间的相关性。dPCR与MFC和qPCR均呈现高度相关性(分别为r = 0.97和r = 0.87),同时具有更高的灵敏度(0.01%),优于MFC(0.1%)和qPCR(1%)。dPCR成为监测CAR-T 细胞动态的一种替代性且高灵敏度的方法。该技术非常适合作为MFC的补充技术在临床实践中应用。
Chimeric antigen receptor T cells (CAR-T) has emerged as a promising therapy, over 60% of patients fail to sustain a long-term response. The underlying factors that leads to the effectiveness of this therapy are not completely understood, CAR-T cell persistence and monitoring seems to be pivotal for ensuring a successful response. Various monitoring methods such as multiparametric flow cytometry (MFC) or quantitative PCR (qPCR) have been applied.
Our objective is to develop digital PCR (dPCR) assays for detection and quantification of CAR-T cells, comparing them with MFC and qPCR. Samples taken at different follow-up times from 45 patients treated with CAR-T therapy were analyzed to assess the correlation between the different methodologies. dPCR presented a high correlation with MFC and qPCR (r = 0.
97 and r = 0. 87, respectively), while offering a higher sensitivity (0. 01%) compared to MFC (0. 1%) and qPCR (1%). dPCR emerged as an alternative and highly sensitivity method for monitoring CAR-T cell dynamics. This technique is well-suited for implementation in clinical practice as a complementary technique to MFC.
MEMBER ACCOUNT
登录成功会直接打开下一页。